Eli Lilly acquires AtaiBeckley for neuroplastogen mental‑health pipeline
- Eli Lilly completed its acquisition of AtaiBeckley.
- AtaiBeckley develops rapid‑acting neuroplastogens; its lead investigational program is BPL-003 for treatment‑resistant depression.
- AtaiBeckley shareholders approved the transaction at a special meeting prior to closing.
- Lilly says it will advance AtaiBeckley’s clinical‑stage pipeline within its neuroscience platform.
Deal completion
Eli Lilly announced the successful completion of its acquisition of AtaiBeckley Inc., a clinical‑stage biopharmaceutical company.
Pipeline and lead program
AtaiBeckley is developing rapid‑acting neuroplastogens for mental health conditions. Its lead investigational program is BPL‑003, which targets treatment‑resistant depression.
Rationale and commitment
Lilly executives framed the assets as a potential shift away from chronic dosing toward rapid‑acting therapeutics and said the company is committed to advancing the programs for patients who need more options.
Approval and risks
The transaction was approved by AtaiBeckley shareholders at a special meeting held prior to closing. Lilly also noted the usual cautions about substantial risks and uncertainties in research, development and realising expected benefits from acquisitions.
Source: Lilly
